Rosenberg, Saul H.

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 3,058

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 1,992

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology

Cell death mechanisms and regulationLymphoma Diagnosis and Treatment

Cited by 876

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Lasko, L. M., Jakob, C. G., Edalji, R. P., Qiu, W., Montgomery, D., Digiammarino, E. L., Hansen, T. M., Risi, R. M., Frey, R., Manaves, V., et al. (2017) · Nature

Histone Deacetylase Inhibitors ResearchProtein Degradation and Inhibitors

Cited by 858

The promise and peril of chemical probes

Arrowsmith, C. H., Audia, J. E., Austin, C., Baell, J., Bennett, J., Blagg, J., Bountra, C., Brennan, P. E., Brown, P. J., Bunnage, M. E., et al. (2015) · Nature Chemical Biology

Click Chemistry and ApplicationsComputational Drug Discovery Methods

Cited by 839

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Leverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M., et al. (2015) · Science Translational Medicine

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 541

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer

Faivre, E. J., McDaniel, K. F., Albert, D. H., Mantena, S. R., Plotnik, J. P., Wilcox, D., Zhang, L., Bui, M. H., Sheppard, G. S., Wang, L., et al. (2020) · Nature

Protein Degradation and InhibitorsProstate Cancer Treatment and Research

Cited by 408

Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents

Xiao, Z., Chen, Z., Gunasekera, A. H., Sowin, T. J., Rosenberg, S. H., Fesik, S., & Zhang, H. (2003) · Journal of Biological Chemistry

DNA Repair MechanismsCancer-related Molecular Pathways

Cited by 388

Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity

Bruncko, M., Wang, L., Sheppard, G. S., Phillips, D. C., Tahir, S. K., Xue, J., Erickson, S., Fidanze, S., Fry, E., Hasvold, L., et al. (2015) · Journal of Medicinal Chemistry

Cell death mechanisms and regulationComputational Drug Discovery Methods

Cited by 164